EGFR and neoplasm: Interestingly, local administration of EGFRvIII-targeting CAR-T cells that simultaneously secrete TCEs against wild-type EGFR, achieved radiographic tumor regression in patients with glioblastoma, and demonstrated a safe profile (7).